Compound: ipriflavone
SMILES: O=c1c(-c2ccccc2)coc3c1ccc(c3)OC(C)C
InChIKey: SFBODOKJTYAUCM-UHFFFAOYSA-N
Synonyms: ipriflavone, 35212-22-7, Osten, Yambolap, 7-Isopropoxyisoflavone, Ipriflavona, Ipriflavonum, Ostivone, 7-(1-Methylethoxy)-3-phenyl-4H-1-benzopyran-4-one, DTXSID5040679, 3-phenyl-7-(propan-2-yloxy)-4H-chromen-4-one, 80BJ7WN25Z, NSC-755888, DTXCID3020679, CHEBI:31719, RefChem:923535, M05BX01, 7-(1-Methylethyl)oxy-3-phenyl-4H-chromen-4-one, 7-Isopropoxy-3-phenyl-4H-1-benzopyran-4-one, Osteofix, Iprosten, Osteoquine, 3-phenyl-7-propan-2-yloxychromen-4-one, 7-isopropoxy-3-phenyl-4H-chromen-4-one, Ipriflavone [INN:JAN], Osten (TN), FL-113, Osteochin, TC 80, FL 113, MFCD00221719, MLS000069470, 7-isopropyloxy-isoflavone, SMR000059060, 4H-1-Benzopyran-4-one, 7-(1-methylethoxy)-3-phenyl-, NCGC00024094-04, Quinogin, Ipriflavone (Osteofix), Iprivone, Ipriflavonum [INN-Latin], Ipriflavona [INN-Spanish], CAS-35212-22-7, CCRIS 1920, BRN 4754346, UNII-80BJ7WN25Z, Ipriflavon, (Ipriflavone), Osten;, Ipriflavone, INN, TC-80, 7-Isopropoxy-3-phenyl-chromen-4-one, 7-isopropoxy-isoflavone, Ipriflavone (Standard), Ipriflavone (JAN/INN), IPRIFLAVONE [MI], Opera_ID_1176, IPRIFLAVONE [INN], IPRIFLAVONE [JAN], Ipriflavone (JP18/INN), IPRIFLAVONE [VANDF], Cambridge id 6663564, cid_3747, IPRIFLAVONE [MART.], Oprea1_106310, Oprea1_275552, IPRIFLAVONE [WHO-DD], MLS000759494, MLS001146879, MLS001424060, MLS006011644, SCHEMBL111472, 7-isopropoxy-3-phenyl-chromone, CHEMBL165790, orb1310736, Ipriflavone, analytical standard, SCHEMBL29485035, BDBM43662, HY-N0094R, SFBODOKJTYAUCM-UHFFFAOYSA-, FL113, HMS2051J15, HMS2234M05, HMS3371E17, HMS3393J15, HMS3656K19, HMS3715D04, HMS5081E03, TN-39, HY-N0094, Tox21_111532, Tox21_113172, MSK169313, s2422, STL512460, AKOS003627375, Tox21_111532_1, Tox21_113172_1, AC-8130, CCG-100963, CS-6395, DB13618, FI07802, NC00213, NSC 755888, 7-(methylethoxy)-3-phenylchromen-4-one, NCGC00018139-01, NCGC00018139-02, NCGC00018139-03, NCGC00018139-04, NCGC00018139-05, NCGC00018139-07, NCGC00018139-08, AS-12306, ST083683, SY057448, 3-phenyl-7-propan-2-yloxy-chromen-4-one, DB-048754, I0669, NS00010326, SW197593-2, 3-phenyl-7-propan-2-yloxy-1-benzopyran-4-one, D01338, D70301, AB00384280-21, F806943, SR-01000000042, Q1097778, SR-01000000042-2, 7-Isopropoxy-3-phenyl-4H-1-benzopyran-4-one, 97%, BRD-K93618743-001-20-2, BRD-K93618743-001-21-0, 3-Phenyl-7-[(propan-2-yl)oxy]-4H-1-benzopyran-4-one, F0196-0909, InChI=1/C18H16O3/c1-12(2)21-14-8-9-15-17(10-14)20-11-16(18(15)19)13-6-4-3-5-7-13/h3-12H,1-2H3
Theoretical properties:
molecular_formula: C18H16O3
molecular_weight: 280.3 g/mol
exact_mass: 280.109944368 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 0
hydrogen_bond_acceptor_count: 3
rotatable_bond_count: 3
heavy_atom_count: 21
topological_polar_surface_area: 35.5 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
melting_point: 115 - 117 °C
Descriptions:
pubchem: Ipriflavone is a member of the class of isoflavones that is isoflavone in which the hydrogen at position 7 is replaced by an isopropoxy group. A synthetic isoflavone, it was formerly used for the treatment of osteoporosis, although a randomised controlled study failed to show any benefit. It is still used to prevent osteoporosis in post-menopausal women. It has a role as a bone density conservation agent. It is an aromatic ether and a member of isoflavones.
chebi: A member of the class of isoflavones that is isoflavone in which the hydrogen at position 7 is replaced by an isopropoxy group. A synthetic isoflavone, it was formerly used for the treatment of osteoporosis, although a randomised controlled study failed to show any benefit. It is still used to prevent osteoporosis in post-menopausal women.
chembl: IPRIFLAVONE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 2.0.
wikipedia: Ipriflavone (INN, JAN; brand name Yambolap) is a synthetic isoflavone which may be used to inhibit bone resorption, maintain bone density and to prevent osteoporosis in postmenopausal women. It is not used to treat osteoporosis. It slows down the action of the osteoclasts (bone-eroding cells), possibly allowing the osteoblasts (bone-building cells) to build up bone mass.
A clinical trial reported in 2001 that it was not effective in prevention or treatment of osteoporosis.
A double-blind study reveals that ipriflavone might be effective on reducing tinnitus on otosclerosis sufferers.
Ipriflavone has been described as a phytoestrogen. However, this is incorrect, as the drug does not bind to or activate the estrogen receptor and shows no estrogenic effects in postmenopausal women. The drug prevents bone loss via mechanisms that are distinct from those of estrogens.